Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 69
Filter
1.
Endoscopy ; 47(9)Sept. 2015. tab
Article in English | BIGG - GRADE guidelines | ID: biblio-964746

ABSTRACT

This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system 1 2 was adopted to define the strength of recommendations and the quality of evidence. Main Recommendations: 1 ESGE recommends endoscopic en bloc resection for superficial esophageal squamous cell cancers (SCCs), excluding those with obvious submucosal involvement (strong recommendation, moderate quality evidence). Endoscopic mucosal resection (EMR) may be considered in such lesions when they are smaller than 10 mm if en bloc resection can be assured. However, ESGE recommends endoscopic submucosal dissection (ESD) as the first option, mainly to provide an en bloc resection with accurate pathology staging and to avoid missing important histological features (strong recommendation, moderate quality evidence). 2 ESGE recommends endoscopic resection with a curative intent for visible lesions in Barrett's esophagus (strong recommendation, moderate quality evidence). ESD has not been shown to be superior to EMR for excision of mucosal cancer, and for that reason EMR should be preferred. ESD may be considered in selected cases, such as lesions larger than 15 mm, poorly lifting tumors, and lesions at risk for submucosal invasion (strong recommendation, moderate quality evidence). 3 ESGE recommends endoscopic resection for the treatment of gastric superficial neoplastic lesions that possess a very low risk of lymph node metastasis (strong recommendation, high quality evidence). EMR is an acceptable option for lesions smaller than 10 - 15 mm with a very low probability of advanced histology (Paris 0-IIa). However, ESGE recommends ESD as treatment of choice for most gastric superficial neoplastic lesions (strong recommendation, moderate quality evidence). 4 ESGE states that the majority of colonic and rectal superficial lesions can be effectively removed in a curative way by standard polypectomy and/or by EMR (strong recommendation, moderate quality evidence). ESD can be considered for removal of colonic and rectal lesions with high suspicion of limited submucosal invasion that is based on two main criteria of depressed morphology and irregular or nongranular surface pattern, particularly if the lesions are larger than 20 mm; or ESD can be considered for colorectal lesions that otherwise cannot be optimally and radically removed by snare-based techniques (strong recommendation, moderate quality evidence).(AU)


Subject(s)
Humans , Barrett Esophagus/surgery , Endoscopy, Gastrointestinal/methods , Dissection , Gastric Mucosa , Gastrointestinal Neoplasms/surgery
2.
Zentralbl Chir ; 137(6): 522-6, 2012 Dec.
Article in German | MEDLINE | ID: mdl-22511020

ABSTRACT

INTRODUCTION: Decompression of bile ducts is the priority objective in the non-curative stage of hilar cholangiocarcinoma. Only this will prevent or slow down infectious complications and secondary biliary cirrhosis thereby sustaining the quality of life. KEY STATEMENTS: At present, photodynamic therapy combined with insertion of an endoprosthesis seems to be best documented and most appropriate therapy. METHODS: Data from a selective literature search combined with our clinical experience were evaluated. CONCLUSIONS: Therapeutic measures should match the dissemination and stage of the tumor: in locally advanced or progressing disease (stage III) a local ablating therapy, in systemically progressing disease (stage IV) systemic chemotherapy should be utilised.


Subject(s)
Bile Duct Neoplasms/surgery , Bile Ducts, Extrahepatic/surgery , Bile Ducts, Intrahepatic/surgery , Cholangiocarcinoma/surgery , Palliative Care/methods , Bile Duct Neoplasms/diagnosis , Bile Duct Neoplasms/pathology , Bile Ducts, Extrahepatic/pathology , Bile Ducts, Intrahepatic/pathology , Brachytherapy , Cholangiocarcinoma/diagnosis , Cholangiocarcinoma/pathology , Combined Modality Therapy , Decompression, Surgical/methods , Hematoporphyrin Photoradiation , Humans , Neoplasm Invasiveness , Neoplasm Staging , Stents
3.
Z Gastroenterol ; 49(11): 1463-9, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22069045

ABSTRACT

BACKGROUND: Peginterferon alpha-2b (PEG-IFNa2b) and lamivudine are efficient treatment options for chronic hepatitis B virus (HBV) infection. We assumed that a combination therapy of PEG-IFNα-2b plus lamivudine will be more effective than PEG-IFNα-2b alone concerning loss of HBV-DNA, HBeAg seroconversion, and HBsAg reduction. PATIENTS AND METHODS: Patients with chronic hepatitis B were randomised to nine months treatment with PEG-IFNα-2b 1.5 µg/kg o. i. w. or PEG- IFNα-2b plus lamivudine 100 mg/d. The study was designed with 60 patients per treatment arm. The primary endpoint was defined as loss of HBV-DNA (< 400 copies/mL) 24 weeks after the end of therapy. HBV-DNA (PCR), HBsAg (Architect, Abbott), and HBeAg (Axsym, Abbott) were determined prior to and at the end of treatment as well as at follow-up. HBV-genotypes were determined by Innolipa (Innogenetics). RESULTS: Only 32 patients were randomised to combination therapy and 27 individuals to monotherapy due to low recruitment rates. On treatment reduction of HBV-DNA was significantly higher during combination therapy compared to PEG-IFNa-2b monotherapy (- 4.60 ± 2.71 vs. - 2.41 ± 2.17 log; p = 0.003). However, there was no difference in the number of cases achieving HBV-DNA < 400 copies/mL, ALT normalisation, or HBeAg seroconversion at follow-up. None of the parameters was significantly related to HBV-genotypes. In a post-hoc analysis serum HBsAg levels were analysed as an additional prognostic parameter for treatment response (n = 29). Combination therapy showed a stronger, but not significant HBsAg decline during (- 0.7 ± 1.17 log IU/mL vs. - 0.26 ± 0.61 log IU/mL; p = 0.35) and after therapy (- 0.68 ± 1.29 log IU/mL vs. - 0.24 ± 0.56 log IU/mL; p = 0.82). Two of three cases with a 2-log HBsAg decline to HBsAg levels < 100 IU/mL eliminated HBsAg during long-term follow-up. CONCLUSION: The study was underpowered with respect to the primary endpoint due to low recruitment rates. However, in the post-hoc analysis HBsAg decline was over two-fold stronger at the end of treatment and follow-up after combination therapy and did not rebound after lamivudine withdrawal. These results may indicate the usefulness of future combination therapies without discontinuation of nucleos(t)ide analogues.


Subject(s)
DNA, Viral/blood , Hepatitis B Surface Antigens/blood , Hepatitis B virus/metabolism , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/drug therapy , Interferon-alpha/administration & dosage , Lamivudine/administration & dosage , Polyethylene Glycols/administration & dosage , Adult , Antiviral Agents/therapeutic use , Cohort Studies , Drug Therapy, Combination , Female , Hepatitis B, Chronic/diagnosis , Humans , Male , Recombinant Proteins/administration & dosage , Treatment Outcome
4.
Lasers Med Sci ; 24(2): 259-68, 2009 Mar.
Article in English | MEDLINE | ID: mdl-18247081

ABSTRACT

Photodynamic therapy (PDT) is a treatment modality for cancer and various other diseases. The clinical protocol covers the illumination of target cells (or tissue), which have been loaded with a photoactive drug (photosensitizer). In this review we describe the photophysical and primary photochemical processes that occur during PDT. Interaction of light with tissue results in attenuation of the incident light energy due to reflectance, absorption, scattering, and refraction. Refraction and reflection are reduced by perpendicular light application, whereas absorption can be minimized by the choice of a photosensitizer that absorbs in the far red region of the electromagnetic spectrum. Interaction of light and the photosensitizer can result in degradation, modification or relocalization of the drug, which differently affect the effectiveness of PDT. Photodynamic therapy itself, however, employs the light-induced chemical reactions of the activated photosensitizer (triplet state), resulting in the production of various reactive oxygen species, amongst them singlet oxygen as the primary photochemical product. Based on these considerations, the properties of an ideal photosensitizer for PDT are discussed. According to the clinical experience with PDT, it is proposed that the innovative concept of PDT is most successfully implemented into the mainstream of anticancer therapies by following an application-, i.e. tumor-centered approach with a focus on the actual clinical requirements of the respective tumor type.


Subject(s)
Optical Phenomena , Photochemical Processes , Photochemotherapy , Humans , Photosensitizing Agents/pharmacology , Scattering, Radiation , Singlet Oxygen/physiology
5.
Z Gastroenterol ; 43(5): 439-43, 2005 May.
Article in German | MEDLINE | ID: mdl-15871065

ABSTRACT

BACKGROUND: If existing biliary drainage is insufficient, photodynamic therapy (PDT, laser treatment after application of a photosensitizer) is an already established adjunct to palliative therapy for progressing hilar cholangiocarcinoma (Klatskin tumours), since it prolongs survival and improves quality of life. Experimental studies of other tumour entities showed that (18)F-FDG-PET ( (18)F-fluorodeosxyglucose-positron emission tomography) may play a role in monitoring tumour response to PDT. Furthermore, previous studies have revealed a high accuracy of this method for the detection of hilar cholangiocarcinoma. Therefore, the aim of the present study was to investigate the feasibility of (18)F-FDG-PET as a follow-up screening method in patients with hilar cholangiocarcinoma who underwent PDT. PATIENTS AND METHODS: 10 patients were examined by (18)F-FDG-PET before and 4 - 6 weeks after PDT. The following parameters were evaluated: maximum and mean SUV in the tumour, the ratio of maximum SUV in the tumour and mean SUV in the liver, the vital tumour volume, as well as bilirubin and CA 19 - 9 levels. RESULTS: All tumours were detected by (18)F-FDG-PET. Within a period of 4 - 6 weeks after PDT the cholestasis parameter bilirubin decreased significantly. However, SUV-associated parameters did not show a significant change after treatment while the estimated vital tumour volume even increased. DISCUSSION: PDT does not effect a relevant reduction of tumour mass in non-resectable hilar cholangiocarcinoma. However, PDT leads to a significant reduction of cholestasis. If (18)F-FDG-PET is suitable for monitoring the effect of new palliative therapeutic approaches, like brachytherapy, the use of modern chemotherapeuticals, COX-2 and receptor-tyrosine kinase inhibitors, perhaps also in combination with PDT, has to be further investigated.


Subject(s)
Bile Duct Neoplasms/diagnostic imaging , Bile Duct Neoplasms/drug therapy , Cholestasis, Intrahepatic/diagnostic imaging , Cholestasis, Intrahepatic/therapy , Fluorodeoxyglucose F18 , Hematoporphyrin Photoradiation , Hepatic Duct, Common , Klatskin Tumor/diagnostic imaging , Klatskin Tumor/drug therapy , Palliative Care , Positron-Emission Tomography , Bile Duct Neoplasms/pathology , Cholestasis, Intrahepatic/pathology , Female , Follow-Up Studies , Hepatic Duct, Common/diagnostic imaging , Hepatic Duct, Common/pathology , Humans , Klatskin Tumor/pathology , Klatskin Tumor/secondary , Male , Neoplasm Staging , Outcome Assessment, Health Care , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/secondary , Ovarian Neoplasms/therapy , Peritoneal Neoplasms/diagnostic imaging , Peritoneal Neoplasms/secondary , Peritoneal Neoplasms/therapy , Prospective Studies
6.
Pediatr Surg Int ; 18(5-6): 503-4, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12415393

ABSTRACT

A 10-year-old boy developed severe obstructive jaundice following blunt abdominal trauma. Endoscopic retrograde cholangiography and magnetic resonance cholangiography revealed a stricture of the common bile duct. A cholecystostomy tube was inserted under laparoscopic guidance. After temporary bile drainage and a cholecystoenteric bypass the patient recovered.


Subject(s)
Bile Ducts, Extrahepatic/injuries , Bile Ducts, Extrahepatic/pathology , Cholecystostomy/methods , Cholestasis, Extrahepatic/surgery , Laparoscopy , Wounds, Nonpenetrating/surgery , Bile Ducts, Extrahepatic/surgery , Child , Cholestasis, Extrahepatic/etiology , Constriction, Pathologic , Humans , Male , Wounds, Nonpenetrating/pathology
8.
J Hepatol ; 35(5): 575-81, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11690702

ABSTRACT

BACKGROUND/AIMS: Wilson disease is caused by a large number of different mutations in the ATP7B gene. Wilson disease patients from a homogeneous ethnical background (Saxonia) were studied for distribution and phenotypes of ATP7B mutations. METHODS: Eighty-two patients were analyzed. The H1069Q mutation was assayed by a polymerase chain reaction-based restriction fragment length polymorphism test. Exons 8 and 15 were sequenced in all, and the entire gene in 30, non-H1069Q-homozygotes. RESULTS: Four novel and 12 known mutations were found. Thirty-two (39%) Wilson disease patients were homozygous and 39 (48%) heterozygous for the H1069Q mutation (allele frequency 63%). Together with sequence analysis of exons 8 and 15 mutations in both alleles were identified in 65% of patients. Only one patient had both mutations at other locations. In H1069Q homozygotes symptoms started later (21.3+/-7.2 years) than in H1069Q compound heterozygotes (14.6+/-5.8, P<0.001) or H1069Q negatives (10+/-4.4, P<0.001), and they had more frequently neurologic symptoms (93 vs. 47%, P<0.001) and Kayser-Fleischer rings (82 vs. 51%, P<0.001). Mutation status did not correlate with liver biopsy findings, serum ceruloplasmin levels or (64)Cu-assay results. CONCLUSIONS: In spite of many known ATP7B mutations, only few occur in this homogeneous population. Limited genetic testing is useful to confirm Wilson disease in this population.


Subject(s)
Adenosine Triphosphatases/genetics , Cation Transport Proteins/genetics , Hepatolenticular Degeneration/genetics , Mutation , Polymorphism, Restriction Fragment Length , Adenosine Triphosphatases/chemistry , Amino Acid Substitution , Cation Transport Proteins/chemistry , Copper/metabolism , Copper-Transporting ATPases , Exons , Genotype , Germany , Heterozygote , Homozygote , Humans , Phenotype , Polymerase Chain Reaction , White People
9.
Transplantation ; 72(1): 116-22, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11468545

ABSTRACT

BACKGROUND: The cytolytic attack of natural killer (NK) cells is blocked by recognition of the idiotypic phenotype of certain polymorphisms in HLA class I molecules, specifically by HLA-C alleles (Asn77, Lys80 or Ser77, Asn80) or HLA-Bw4 allotypes. Because liver allograft rejection is associated closer with mismatch in HLA class I than class II, we investigated the role of NK cells in acute hepatic allograft rejection in vivo/in vitro. METHODS: The HLA pattern was typed with serological and polymerase chain reaction (PCR) techniques. In 31 liver transplantations, mononuclear cells from donor spleen and peripheral blood of recipients (before/after transplantation) were cultured in mixed lymphocyte cultures (MLC). MLC-derived effector cells were analyzed by flow cytometry and tested in 51Cr-release assays. RESULTS: Patients with NK allospecific constellations tended to have higher numbers of NK cells in peripheral blood during the first 4 weeks after transplantation, and patients' lymphocytes stimulated with donor cells had a significantly higher cytotoxic activity on days 14 and 21 compared with patients without NK allospecificity. However, acute rejection occurred with similar frequency in both groups (31% with allospecific constellations vs. 40% without). Moreover, acute rejection episodes were not associated with an increase in NK cells in vivo or enhanced cytotoxicity of NK cells to donor target cells. CONCLUSIONS: Under standard immunosuppressive therapy, NK allospecific constellations did not seem play a major role in acute hepatic allograft rejection. Strategies to prevent or treat NK allospecific constellations after liver transplantation are not likely to reduce the incidence or severity of acute allograft rejection.


Subject(s)
Isoantibodies/analysis , Killer Cells, Natural/immunology , Liver Transplantation/immunology , Acute Disease , Adolescent , Adult , Cells, Cultured , Cytotoxicity, Immunologic , Female , Graft Rejection/immunology , Humans , Killer Cells, Natural/pathology , Leukocyte Count , Lymphocyte Culture Test, Mixed , Male , Middle Aged , Transplantation, Homologous
10.
Hepatology ; 33(5): 1029-35, 2001 May.
Article in English | MEDLINE | ID: mdl-11343227

ABSTRACT

Malignant tumors with high glucose metabolic rates accumulate [18F]-fluorodeoxyglucose (FDG), a positron emitting tracer. The aim of this study was to evaluate FDG positron emission tomography (PET) for detection and staging of human cholangiocarcinoma (CC). Patients with adenocarcinoma of the biliary tree (n = 26), with benign lesions of the bile ducts (n = 8), and 20 control patients underwent FDG-PET (370 MBq [18F]-FDG, Siemens ECAT EXACT HR(+)). In a blinded fashion, 4 independent experts evaluated the PET scans visually and semiquantitatively using the standardized uptake value and a tumor/non-tumor ratio. All adenocarcinomas and benign lesions (sclerosing cholangitis, bile duct adenoma, Caroli's disease) were histologically proven and imaged by magnetic resonance imaging and endoscopic retrograde cholangioscopy. True-positive PET scans were obtained in 24 of 26 CC and false-negative scans in the other 2 (sensitivity 92.3%). The PET scan was true-negative in 18 of 20 controls and in all 8 benign biliary lesions (specificity 92.9%). Visual and semiquantitative evaluation using tumor/non-tumor ratios were equally accurate (accuracy 92.6%) whereas evaluation by standardized uptake value revealed lower accuracy (P <.05). Regional or hepatoduodenal lymph node metastases were detected with PET in only 2 of 15 cases whereas distant metastases (peritoneal carcinomatosis, pulmonary metastases) were diagnosed in 7 of 10 cases. In conclusion, PET is highly sensitive and specific for the detection and localization of CC. It can be helpful for diagnosis of distant metastases but is not suitable for detection of regional lymph node metastases.


Subject(s)
Bile Duct Neoplasms/diagnostic imaging , Bile Duct Neoplasms/diagnosis , Cholangiocarcinoma/diagnostic imaging , Cholangiocarcinoma/diagnosis , Tomography, Emission-Computed , Adenocarcinoma/diagnosis , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/pathology , Adult , Aged , Aged, 80 and over , Bile Duct Diseases/diagnosis , Bile Duct Neoplasms/pathology , Cholangiocarcinoma/pathology , Cholangiocarcinoma/secondary , Female , Fluorodeoxyglucose F18 , Humans , Lymphatic Metastasis , Magnetic Resonance Imaging , Male , Middle Aged , Neoplasm Staging/methods , ROC Curve , Radiography , Radiopharmaceuticals , Reference Values
13.
Z Gastroenterol ; 39 Suppl 2: 13-4, 2001 Jun.
Article in English | MEDLINE | ID: mdl-16215886

ABSTRACT

This is a case report of a 36 years old man who has been suffering for 20 years from benign recurrent intrahepatic cholestasis (BRIC). BRIC is a rare autosomal recessive disease characterised by prolonged episodes of intrahepatic cholestasis and pruritus alternating with periods of nearly normal liver function, and does not progress to cirrhosis. Since all former approaches to medical treatment of the patients severe pruritus were ineffective, the patient was treated by 3 sessions of albumin dialysis (MARS, Molecular Adsorbents Recirculating System). MARS dialysis decreased serum bilirubin levels by more than 60 % and effectively lowered serum bile acid levels by 45 %. The course of serum parameters was accompanied by a dramatic clinical improvement of the patients symptoms (pruritus, jaundice, fatigue etc.). MARS therapy appeared to shorten the duration of the cholestatic attack.


Subject(s)
Blood Component Removal/methods , Cholestasis, Intrahepatic/prevention & control , Extracorporeal Circulation/methods , Renal Dialysis/methods , Serum Albumin/isolation & purification , Adult , Humans , Male , Recovery of Function , Secondary Prevention , Treatment Outcome
14.
Cell Mol Biol (Noisy-le-grand) ; 47 Online Pub: OL149-57, 2001.
Article in English | MEDLINE | ID: mdl-11936861

ABSTRACT

Mutations in the Wilson disease gene ATP7B, a P-type ATPase, are responsible for copper accumulation in the liver and other organs leading to Wilson disease (WD, OMIM 277900). Clinical manifestations of Wilson disease (WD) include chronic liver disease, acute hepatic failure or neuropsychiatric diseases. Since potent medical treatments are available to prevent disabling residual symptoms, early diagnosis is crucial. To demonstrate the clinical course and genetic findings, a male patient with a novel mutation in the ATP7B gene, a 10 base pair insertion in exon 6 (1927ins 10), and a second missense mutation in exon 13 (P992L) is reported. The patient presented with signs of chronic liver disease at the age of 10 years. Clinical findings included hepatomegaly, elevated liver enzymes and coagulopathy. A combination treatment with the copper chelating agent D-penicillamine and zinc acetate was started leading to normalization of liver function and no appearance of neurological signs or Kayser-Fleischer ring after 7 years follow-up. Truncating mutations of the ATP7B gene (insertions, deletions, nonsense mutations) leading to gross loss of C-terminal parts of the protein, thereby probably completely destroying the protein function, may correlate with a hepatic phenotype and early onset as seen in the patient presented.


Subject(s)
Adenosine Triphosphatases/genetics , Cation Transport Proteins/genetics , Copper/metabolism , Hepatolenticular Degeneration/genetics , Hepatolenticular Degeneration/metabolism , Mutation , Adolescent , Base Sequence , Copper/urine , Copper-Transporting ATPases , DNA/genetics , DNA Mutational Analysis , Exons , Genotype , Hepatolenticular Degeneration/drug therapy , Humans , Male , Mutation, Missense , Penicillamine/therapeutic use , Phenotype , Zinc Acetate/therapeutic use
15.
FEBS Lett ; 484(2): 77-81, 2000 Nov 03.
Article in English | MEDLINE | ID: mdl-11068036

ABSTRACT

Cyclin B is an important regulator of progression through the cell division cycle. The oscillating appearance of cyclin B1 and B2 proteins during the cell cycle is in part due to fluctuating mRNA levels. We had identified earlier a tandem promoter element named cell cycle-dependent element (CDE) and cell cycle genes homology region (CHR) which regulates cell cycle-dependent transcription of cdc25C, cyclin A and cdc2. Here we describe that cyclin B2 transcription is repressed through a novel CDE/CHR element in resting and G(1) cells. By relief of this repression in S and G(2) oscillating expression of cyclin B2 mRNA is achieved during the cell cycle.


Subject(s)
Cyclin B/genetics , Promoter Regions, Genetic/genetics , Tandem Repeat Sequences/genetics , Animals , Base Sequence , Cell Cycle/genetics , Cells, Cultured , Cyclin B/metabolism , Cyclin B2 , DNA/analysis , Gene Silencing , Mice , Molecular Sequence Data , Sequence Homology, Nucleic Acid , Simian virus 40/genetics , Transcription, Genetic
16.
Liver Transpl ; 6(6): 728-33, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11084059

ABSTRACT

Acute rejection of hepatic allografts does not show consistent association with the number of mismatches of HLA classes I and II. Therefore, we investigated the relation between specific donor or recipient HLA antigens and the occurrence of acute rejection. HLA typing of 35 liver transplant recipients and donors was performed by serological standard technique, with confirmation and subtyping by polymerase chain reaction with sequence-specific primers. HLA class I antigens were not associated with the occurrence of acute rejection. The graft was positive for HLA-DR13 in 8 of 13 transplant recipients (62%) with acute rejection, but only 4 of 22 recipients (18%; P =.024; P(Bonferroni-corrected) =.33, not significant) without rejection. The graft was positive for DRB1*1301 in 7 of 13 recipients (54%) with acute rejection, but only 1 of 22 recipients (5%) without rejection (P =.002; P(Bonferroni-corrected )=.028). This patient had experienced long-lasting bacterial sepsis, which markedly reduced the risk for acute rejection. We speculate that the expression of donor DRB1*1301 (if mismatched) may increase the risk for acute hepatic allograft rejection.


Subject(s)
Graft Rejection/immunology , HLA-DR Antigens/genetics , Liver Transplantation/immunology , Tissue Donors , Acute Disease , Adult , Alleles , Biomarkers , Biopsy , Drug Therapy, Combination , Graft Rejection/pathology , Graft Rejection/prevention & control , HLA-DR Antigens/immunology , HLA-DR Serological Subtypes , Histocompatibility Testing , Humans , Immunosuppressive Agents/therapeutic use , Prognosis , Prospective Studies , Severity of Illness Index , Transplantation, Homologous
17.
Chirurg ; 71(6): 667-75, 2000 Jun.
Article in German | MEDLINE | ID: mdl-10948733

ABSTRACT

Clinical liver transplantation became an established therapy of end-stage liver disease since the first at least medium-term successful liver transplantation in 1967. Clinical studies have played a major part in improving peri- and postoperative therapy in liver transplantation. In this article clinical studies of major impact are presented. Main topics are studies dealing with immunosuppressants, improvements in surgical techniques, viral infections and tumor diseases. Controlled randomized multicentric studies are rare; most of the studies are unicentric. Further studies in the fields of reducing side effects of immunosuppression, the introduction of monoclonal antibodies and improvement of the therapy of viral hepatitis would be helpful. These studies should be controlled, randomized and multicentric.


Subject(s)
Liver Transplantation , Multicenter Studies as Topic , Randomized Controlled Trials as Topic , Carcinoma, Hepatocellular/surgery , Cyclosporine/therapeutic use , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/etiology , Double-Blind Method , Hepatitis B/complications , Hepatitis B/etiology , Hepatitis C/complications , Hepatitis C/etiology , Humans , Immunosuppression Therapy , Immunosuppressive Agents/therapeutic use , Liver Neoplasms/surgery , Liver Transplantation/adverse effects , Liver Transplantation/methods , Postoperative Complications , Prognosis , Prospective Studies , Tacrolimus/therapeutic use
18.
Hepatology ; 32(1): 91-6, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10869294

ABSTRACT

From August 1978 until March 1979, 14 batches of anti-D immune globulin contaminated with hepatitis C virus (HCV) genotype 1b (20, 000-480,000 copies/dose) from a single erythrocyte donor had been administered for prophylaxis of rhesus isoimmunization throughout East Germany. All 2,867 women involved had been recalled after January 12, 1979 for repeated screening of alanine transaminase (ALT). They were prospectively followed in regional centers. We have reexamined a cohort of 1,018 women (median age 24, range 16-38 years at infection) on follow-up for 20 years in 9 representative centers. Within 6 months after anti-D administration, 10% of these women had no evidence of disease and 90% had acute hepatitis C (n = 917) including 49% with symptomatic and 22% with icteric course. After 20 years, 85% of the 917 affected women still tested positive for HCV antibodies (among them 3% responded to interferon treatment) and 55% were positive for HCV RNA (among them 7% were nonresponders to interferon and 3% were apparent HCV carriers). Only 4 (0.4%) had overt cirrhosis. Two (0.2%) died of superinfected fulminant hepatitis B or alcoholism and cirrhosis, respectively. Histology obtained in 44% of the viremic women showed hepatitis of minimal to moderate grade in 96%, portal fibrosis in 47%, and septal fibrosis in 3% of the cases. In conclusion, formerly healthy young women, without hepatic comorbidity, may clear HCV (1b) infection in half of the cases or develop mild chronic hepatitis C with low risk of progression to cirrhosis within 20 years.


Subject(s)
Hepatitis C/complications , Liver Cirrhosis/etiology , Adolescent , Adult , Alanine Transaminase/blood , Disease Outbreaks , Female , Follow-Up Studies , Germany/epidemiology , Hepacivirus/classification , Hepatitis C/epidemiology , Hepatitis C/virology , Humans , Liver/pathology , Middle Aged , Prospective Studies
19.
J Hepatol ; 32(2): 352-7, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10707878

ABSTRACT

BACKGROUND: Hilar bile duct carcinoma has an 80% probability of local recurrence after curative resection, which might be reduced if neoadjuvant photodynamic therapy is feasible. CASE AND TREATMENT: After intravenous injection of sodium porfimer we treated an adenocarcinoma of the proximal common bile duct (T2 N0 M0, Bismuth type II) in a 72-year-old man with red laser light (applied from the lumen at a dose 250 Joules/cm2), and the adjacent right and left hepatic and common bile duct at a dose of 125 Joules/cm2. After 23 days the tumor was completely resected (adenocarcinoma pT2 pNO; G2). RESULTS: In the lumenal, 4-mm-thick layer the bile duct specimen exhibited complete tumor necrosis with pigmentation of photodegraded porfimer and no viable tumor cells, while in the outer layer of the wall (at 5-8-mm depth) viable cancer cell nests without degraded porfimer were seen. The bile duct tissue showed little damage. Eighteen months after surgery, neither tumor recurrence nor stricture formation was found at the pretreated bilioenteric anastomoses. CONCLUSIONS: a) Photodynamic therapy with sodium porfimer seems to be confined to the superficial 4-mm layer of bile duct cancer. b) Neoadjuvant photodynamic therapy is feasible for hilar bile duct carcinoma.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/surgery , Bile Duct Neoplasms/drug therapy , Bile Duct Neoplasms/surgery , Common Bile Duct , Neoadjuvant Therapy , Photochemotherapy , Aged , Antineoplastic Agents/therapeutic use , Cholangiopancreatography, Endoscopic Retrograde , Combined Modality Therapy , Dihematoporphyrin Ether/therapeutic use , Feasibility Studies , Humans , Injections, Intravenous , Male
20.
J Hepatol ; 32(1): 4-10, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10673060

ABSTRACT

BACKGROUND/AIMS: The development of cholesterol gallstones, in some patients, has been associated with increased proportions of deoxycholic acid in the bile acid pool. Deoxycholic acid is a microbial product of cholic acid 7alpha-dehydroxylation in the intestines. The levels and activities of bile acid 7alpha-dehydroxylating bacteria have been reported to be increased in gallstone patients. The aim of the current study was to isolate 7alpha-dehydroxylating bacteria from gallstone patients and determine if these individuals are colonized by similar bacterial species. METHODS: The levels of 7alpha-dehydroxylating bacteria in fecal samples were determined by fecal dilutions in 24 gallstone patients and 10 controls. 7alpha-Dehydroxylating bacteria were isolated by a non-selective streak plate technique and 7alpha-dehydroxylation activity was determined by measuring the conversion of [14C]-cholic acid to [14C]-deoxycholic acid using thin-layer chromatography. RESULTS: Gallstone patients had >42-fold (p<0.01) higher levels of 7alpha-dehydroxylating bacteria than patients who had not developed gallstones. Eighteen strains of 7alpha-dehydroxylating bacteria were isolated from eight gallstone patients. Attempts to isolate 7alpha-dehydroxylating bacteria from ten control patients were unsuccessful using identical isolation techniques. Surprisingly, all strains of bacteria isolated from gallstone patients appear to belong to the genus Clostridium. CONCLUSION: Gallstone patients have higher levels of 7alpha-dehydroxylating fecal bacteria and appear to harbor only members of the genus Clostridium with this activity.


Subject(s)
Cholelithiasis/microbiology , Cholesterol , Cholic Acids/metabolism , Clostridium/metabolism , Eubacterium/metabolism , Feces/microbiology , Steroid Hydroxylases/metabolism , Adult , Aged , Bacterial Typing Techniques , Blotting, Southern , Cholic Acid/metabolism , Chromatography, Thin Layer , Clostridium/genetics , Clostridium/isolation & purification , Colony Count, Microbial , DNA, Bacterial/analysis , Deoxycholic Acid/metabolism , Eubacterium/genetics , Eubacterium/isolation & purification , Female , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...